课题基金 / 基金详情

BIOCHEMICAL AND HISTOCHEMICAL EXAMINATIONS ON LIPJD-BINDING PROTEINS (LBP), PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) AND RETINOL RECEPTORS (RXR) IN KIDNEY.

BIOCHEMICAL AND HISTOCHEMICAL EXAMINATIONS ON LIPJD-BINDING PROTEINS (LBP), PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) AND RETINOL RECEPTORS (RXR) IN KIDNEY.
肾脏中 LIPJD 结合蛋白 (LBP)、过氧化物酶体增殖物激活受体 (PPAR) 和视黄醇受体 (RXR) 的生化和组织化学检查。
批准号:
12671034
负责人:
KIMURA Hideki
金额:
$2.18万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001

项目摘要

项目成果

KIMURA Hideki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
1. Investigation on the expression ofLBPs and PPARs in normal and diseased human kidneys.(1) In normal human kidney, liver type (L-) fatty acid-binding protein (FABP) and heart-type FABP were predominantly localized in cytoplasm of proximal and distal renal tubular epithelial cells (RTEC), respectively. PPAR-α was mainly present in cytoplasm of proximal RTEC and PPAR-γ was present in cytoplasm of distal RTEC and collecting ducts.(2) As for transplanted kidneys suffering from severe hypoxia, the expressions of L-FABP and PPAR-α were increased in cytoplasm of some proximal RTECs. In interstitial nephritis, nuclear stainings for L-FABP and PPAR-α were found in some proximal RTECs, suggesting the interaction between L-FABP and PPAR-α. Purified L-FABP contained endogenously long-chain fatty acids which can serve as ligands, stimulators for PPAR-α. In interstitial nephritis, PPAR-α was expressed in infiltrating eosinophils but not macrophages. In membranous nephropathy, nuclear staining for … More PPAR-α was more frequent than normal kidney.2. Investigation on the expression of LBPs and PPARs in human cultured proximal renal tubular epithelial cells.(1) Indirect immunofluorescence method and immunoblotting revealed that L-FABP and PPAR-α were expressed in human cultured proximal renal tubular epithelial cells. PAI-1 was also expressed in the cultured cells.(2) PAI-1 antigen was detected in the medium of human cultured proximal renal tubular cells at a concentration of 250-600 ng/mL after the cells were cultured in the medium including several growth factors and bioactive molecules. Addition of hydrocortisone and epinephrine to the basic medium increased the concentration of PAI- 1 in the conditioned medium of the cultured cells. Hypoxia appeared to induce further the expression of PAI-1 in the cells cultured in the growth medium.3. Analysis of relationships between clinical variables and advanced renal disease and vascular disease.In hemodialysis patients with high HDL-C status, cholesteryl ester transfer protein (CETP) was a protective factor against vascular disease. A common C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene was associated with increased serum levels of homocysteine which causes oxidative stress to endothelial cells. The homozygous mutants (TT genotype) were younger at the induction of hemodialysis and had a shorter duration of dialysis, suggesting that hyperhomocysteinemia may be related to accelerated progression of renal damage and mortality after initiation of dialysis. Among diabetic patients, PAI-1 concentrations in urine were higher in those with severe proteinuria over 1000 mg/gCr than those with microalbuminuria, while plasma PAI-1 levels were unchanged during progression of diabetic nephropathy. Urinary PAI-1 levels were positively associated with urinary NAG and sugar levels. Less
期刊论文(23)
专著(0)
科研奖励(0)
会议论文
Tsukahara H.: "Methylenetetrahydrofolate reductase polymorphismin Kawasaki disease"Pediat. Int.. 742. 236-240 (2001)
Tsukahara H.:“川崎病中的亚甲基四氢叶酸还原酶多态性”Pediat。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kimura H: "Cholesteryl ester transfer protein as a protective factor against vascular disease in hemodialysis patients"Am. J. Kidney Dis.. (2001)
Kimura H:“胆固醇酯转移蛋白作为血液透析患者血管疾病的保护因子”Am。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kimura H: "AC677T mutation in the methylenetetrahydrofolate reductase gene modifies serum cysteine in dialysis patients"Am. J. Kidney Dis.. 36. 925-933 (2000)
Kimura H:“亚甲基四氢叶酸还原酶基因中的 AC677T 突变会改变透析患者的血清半胱氨酸”Am。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Tsukahara H: "Methylenetetrahydrofolate reductase polymorphism in Kawasaki disease"Pediat. Int.. 42. 236-240 (2000)
Tsukahara H:“川崎病中的亚甲基四氢叶酸还原酶多态性”Pediat。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
23
    Analysis of anti-fibrotic effects of lipid-responsible transcription factors and a search for new therapeutic agents -with special attention to hypoxic insults-
    • 批准号:
      24591193
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.33万
    • 财政年份:
      2012
    • 负责人:
      KIMURA Hideki
    • 依托单位:
    Investigation for anti-renal fibrotic effects of lipid-binding proteins and lipid-activated nuclear receptors and search for new therapeutic reagents
    • 批准号:
      21591024
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.83万
    • 财政年份:
      2009
    • 负责人:
      KIMURA Hideki
    • 依托单位:
    Diachronic Changes and Panchronic Universal Properties of Constructions and Grammatical Categories in Chinese-a Reconstruction of Historical Chinese Grammar
    • 批准号:
      19320057
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.9万
    • 财政年份:
      2007
    • 负责人:
      KIMURA Hideki
    • 依托单位:
    Analysis for anti-inflammatory and anti-fibrotic actions of lipid transfer proteins and lipid-activated transcription factors in the progressive renal injury
    • 批准号:
      19590944
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.83万
    • 财政年份:
      2007
    • 负责人:
      KIMURA Hideki
    • 依托单位:
    国内基金
    海外基金
    稳定期COPD中医证型的脂代谢紊乱特征及PPARγ/CPT1A调控机制及临床研究
    • 批准号:
      JCZRLH202601649
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    基于“郁痰”理论探讨海藻消瘤胶囊调控ERα-PPARγ轴抑制PTC细胞代谢失衡的作用机制
    IPA靶向FABP4/PPARγ信号通路改善肥胖相关性肾小球疾病
    • 批准号:
      2026JJ81107
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      贺超
    • 依托单位:
    M2巨噬细胞外泌体通过MEG3/PPARγ/Nrf2轴介导铁死亡抑制子痫前期进展的作用及机制研究
    • 批准号:
      2026JJ50641
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      喻玲
    • 依托单位: